Treatment of Mrsa Pneumonia: Economical and Clinical Comparison of Linezolid Verse Vancomycin.

Infections with methicillin resistant Staphylococcus aureus (MRSA) pathogens represent a substantial economic burden for the healthcare system. As the main cost driver, the increase in the length of stay (LOS) in hospital has been identified. The expenses directly related to the antibiotics used for the treatment of MRSA infections, in contrast, were found to be relatively marginal. Nevertheless, the purchase price of an antibiotic is often used as a criterion for the decision regarding the appropriate antibiotic treatment (e.g. [1]).